Arcus Biosciences, Inc. Property, Plant and Equipment, Gross
Arcus Biosciences, Inc. (RCUS) had Property, Plant and Equipment, Gross of $90.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-02-25
- 2025-12-31: Property, Plant and Equipment, Gross $90.00M.
- 2024-12-31: Property, Plant and Equipment, Gross $88.00M.
- 2023-12-31: Property, Plant and Equipment, Gross $82.00M.
- 2022-12-31: Property, Plant and Equipment, Gross $58.00M.
| Period end | Property, Plant and Equipment, Gross | Property, Plant and Equipment, Gross as first filed |
|---|---|---|
| 2025-12-31 | $90.00M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $88.00M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $82.00M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $58.00M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $50.00M 10-K · filed 2023-02-28 | $50.18M 10-K · filed 2022-02-23 |
| 2020-12-31 | $25.09M 10-K · filed 2022-02-23 | |
| 2019-12-31 | $20.55M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $20.38M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $19.84M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $19.62M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $18.75M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $18.46M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $18.23M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $16.62M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $15.21M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |